SwissNET - a Registry for Neuroendocrine Tumours in Switzerland (SwissNET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01039922|
Recruitment Status : Recruiting
First Posted : December 25, 2009
Last Update Posted : January 23, 2020
|Condition or disease|
|Neuroendocrine Tumors Carcinoid Tumor|
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are generally classified as rare diseases. Little is known about their cell biology and their mechanistic regulation. During the last years, the incidence of GEP-NETs is continuously increasing worldwide. In parallel, novel treatment options are currently evaluated which may substantially improve prognosis of patients with NETs. Data on such tumours in Switzerland, however, is scarce and treatment strategies vary throughout the country.
To systematically and prospectively collect clinical information of patients with GEP-NETs in Switzerland based on a histologically confirmed diagnosis.
All NETs of both, gastrointestinal and pulmonary origin are included provided that patients have given informed consent. Data will be entered prospectively and anonymised in a specifically designed database. Contributing centres and general practitioners are visited by a study nurse, patient files are analysed and data is transferred to the database. In case of conflicting evidence, questions are resolved in collaboration with a review board of SwissNET. Evaluation of treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate) will take place within regular time frames.
|Study Type :||Observational|
|Estimated Enrollment :||1245 participants|
|Official Title:||SwissNET - a Prospective Registry of Patients With Neuroendocrine Tumours in Switzerland|
|Study Start Date :||January 2008|
|Estimated Primary Completion Date :||January 2028|
|Estimated Study Completion Date :||January 2028|
Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
- Tumor-related mortality [ Time Frame: Every 5 years ]
- Incidence of GEP-NET in Switzerland [ Time Frame: Every 5 years ]
- Effect of specific treatment strategies [ Time Frame: Every 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01039922
|Contact: Alexander Siebenhuener, MD||++41 44 255 2214||Alexander.Siebenhuener@usz.ch|
|Contact: Emanuel Christ, MD, PhD||++41 31 632 40 firstname.lastname@example.org|
|Study Director:||Aurel Perren, MD||Institute of Pathology, University of Bern, Bern|